RhumbLine Advisers’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$301M Sell
611,950
-688
-0.1% -$373K 0.26% 59
2025
Q4
$355M Sell
612,638
-11,564
-2% -$6.54M 0.29% 51
2025
Q3
$303M Sell
624,202
-10,853
-2% -$5.05M 0.24% 61
2025
Q2
$257M Sell
635,055
-23,302
-4% -$9.74M 0.22% 72
2025
Q1
$328M Sell
658,357
-6,255
-0.9% -$3.39M 0.31% 46
2024
Q4
$346M Sell
664,612
-10,559
-2% -$5.81M 0.31% 46
2024
Q3
$418M Sell
675,171
-21,512
-3% -$12.7M 0.38% 37
2024
Q2
$385M Sell
696,683
-16,283
-2% -$9.33M 0.36% 36
2024
Q1
$414M Buy
712,966
+412
+0.1% +$231K 0.4% 35
2023
Q4
$378M Sell
712,554
-3,810
-0.5% -$1.84M 0.4% 36
2023
Q3
$363M Buy
716,364
+2,592
+0.4% +$1.38M 0.42% 34
2023
Q2
$372M Buy
713,772
+14,229
+2% +$7.68M 0.42% 35
2023
Q1
$403M Buy
699,543
+9,863
+1% +$5.56M 0.5% 29
2022
Q4
$380M Buy
689,680
+30,462
+5% +$16.1M 0.51% 30
2022
Q3
$334M Buy
659,218
+15,258
+2% +$8.54M 0.5% 28
2022
Q2
$350M Buy
643,960
+30,674
+5% +$16.9M 0.51% 28
2022
Q1
$362M Buy
613,286
+12,712
+2% +$7.3M 0.47% 32
2021
Q4
$401M Buy
600,574
+5,105
+0.9% +$3.19M 0.49% 28
2021
Q3
$340M Sell
595,469
-13,422
-2% -$7.37M 0.46% 32
2021
Q2
$307M Sell
608,891
-31,721
-5% -$15M 0.4% 42
2021
Q1
$292M Sell
640,612
-43,793
-6% -$20.9M 0.4% 43
2020
Q4
$319M Sell
684,405
-6,331
-0.9% -$2.97M 0.44% 38
2020
Q3
$305M Buy
690,736
+28,506
+4% +$11.8M 0.48% 36
2020
Q2
$240M Buy
662,230
+29,799
+5% +$9.99M 0.4% 42
2020
Q1
$179M Buy
632,431
+2,511
+0.4% +$792K 0.38% 50
2019
Q4
$205M Sell
629,920
-1,202
-0.2% -$364K 0.34% 56
2019
Q3
$184M Buy
631,122
+8,242
+1% +$2.36M 0.34% 55
2019
Q2
$183M Sell
622,880
-11,308
-2% -$3.11M 0.34% 52
2019
Q1
$174M Sell
634,188
-17,848
-3% -$4.44M 0.34% 60
2018
Q4
$146M Buy
652,036
+7,916
+1% +$1.86M 0.32% 57
2018
Q3
$157M Sell
644,120
-9,090
-1% -$2.09M 0.3% 63
2018
Q2
$135M Buy
653,210
+19,282
+3% +$4.09M 0.27% 67
2018
Q1
$131M Sell
633,928
-6,101
-1% -$1.28M 0.27% 67
2017
Q4
$122M Buy
640,029
+21,515
+3% +$4.12M 0.25% 79
2017
Q3
$117M Buy
618,514
+20,031
+3% +$3.63M 0.25% 76
2017
Q2
$104M Sell
598,483
-4,787
-0.8% -$804K 0.24% 81
2017
Q1
$92.7M Sell
603,270
-13,306
-2% -$2.03M 0.22% 89
2016
Q4
$87M Buy
616,576
+23,809
+4% +$3.51M 0.22% 89
2016
Q3
$94.3M Buy
592,767
+60,752
+11% +$9.36M 0.26% 73
2016
Q2
$78.6M Buy
532,015
+19,813
+4% +$2.92M 0.23% 85
2016
Q1
$72.5M Buy
512,202
+19,744
+4% +$2.65M 0.23% 89
2015
Q4
$69.9M Sell
492,458
-2,130
-0.4% -$284K 0.22% 83
2015
Q3
$60.5M Sell
494,588
-3,097
-0.6% -$403K 0.21% 91
2015
Q2
$64.6M Sell
497,685
-87,102
-15% -$11.4M 0.21% 97
2015
Q1
$78.6M Sell
584,787
-985
-0.2% -$127K 0.23% 95
2014
Q4
$73.4M Sell
585,772
-10,558
-2% -$1.28M 0.21% 102
2014
Q3
$72.6M Sell
596,330
-4,081
-0.7% -$496K 0.22% 102
2014
Q2
$70.8M Buy
600,411
+25,088
+4% +$2.95M 0.21% 101
2014
Q1
$69.2M Buy
575,323
+17,489
+3% +$2.08M 0.21% 103
2013
Q4
$62.1M Sell
557,834
-24,059
-4% -$2.39M 0.18% 118
2013
Q3
$53.6M Sell
581,893
-8,043
-1% -$727K 0.17% 130
2013
Q2
$49.9M Buy
+589,936
New +$49.1M 0.16% 130

Other funds holding TMO

RhumbLine Advisers's TMO Position: Q1 2026 in Review

RhumbLine Advisers reduced its Thermo Fisher Scientific (TMO) stake by 0.11% in Q1 2026, selling an estimated $373K and leaving 611,950 shares worth $301M. The position accounts for 0.26% of the portfolio, ranked #59.

RhumbLine Advisers first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $418M in Q3 2024. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • RhumbLine Advisers held 611,950 shares of Thermo Fisher Scientific worth $301M as of Q1 2026.
  • RhumbLine Advisers sold 688 Thermo Fisher Scientific shares in Q1 2026, an estimated $373K.
  • Thermo Fisher Scientific made up 0.26% of RhumbLine Advisers's portfolio in Q1 2026, its #59 holding.
  • RhumbLine Advisers first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
  • RhumbLine Advisers's Thermo Fisher Scientific position peaked at $418M in Q3 2024.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.